SOURCE: NuPathe Inc.

NuPathe Inc.

June 21, 2012 08:00 ET

NuPathe to Present Migraine Patch Data at American Headache Society Meeting

Positive Data Support Long-Term Tolerability and Consistency of Drug Delivery With and Without Controlled Heat

CONSHOHOCKEN, PA--(Marketwire - Jun 21, 2012) - NuPathe Inc. (NASDAQ: PATH), a biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that the Company will present data on its migraine patch at the upcoming 54th Annual Scientific Meeting of the American Headache Society (AHS), which takes place June 21-24, 2012 in Los Angeles, CA.

The AHS presentations are:

  • "Long Term Safety of the Sumatriptan Iontophoretic Transdermal Patch, NP101, For Acute Migraine: A 12 Month, Repeat Use, Open Label Study": These final study results involving 7,665 patch applications show that NP101 was well-tolerated with an adverse event profile similar to previous NP101 studies.

  • "A Phase I, Single Center, Open Label, Randomized, Single-Dose, Two Way Crossover Study to Compare the Pharmacokinetics of Two NP101 Patch Applications (Sumatriptan Iontophoretic Transdermal System) With and Without Controlled Heat": These data indicate that the addition of heat applied to the patch for the four-hour application time does not increase drug exposure.

All poster presentations are presented at the Hyatt Regency Century Plaza in Los Angeles, CA, from 11:00 am on Thursday, June 21 through 2:15 pm on Saturday, June 23. Authors will stand by their posters to answer questions during the following times: Friday, June 22 from 12:45 pm - 2:00 pm and Saturday, June 23 from 1:00 pm - 2:15 pm. All times are Pacific Daylight Time.

About the Migraine Patch (NP101 or Zelrix)
NP101 is an active, single-use, transdermal patch in development for the treatment of migraine. If approved, it will be the first transdermal patch for the treatment of migraine. The patch actively delivers sumatriptan, the most widely prescribed migraine medication. In three clinical trials involving more than 10,000 applications, NP101 offered patients fast onset and sustained relief of debilitating migraine symptoms including headache pain and migraine-related nausea (MRN). Because NP101 delivers sumatriptan transdermally, it may be an attractive treatment option for many of the approximately seven million migraineurs who might otherwise delay or avoid taking medication due to MRN. In addition, clinical trials suggest that many migraineurs fail to respond consistently to orally administered medications. This may result from a variety of causes including gastroparesis, a slowing of gastric absorption experienced by some migraine sufferers. The patch utilizes SmartRelief™, NuPathe's proprietary transdermal delivery technology that allows the rapid yet tightly controlled transport of medication through the skin using a process called iontophoresis. As a result and based on clinical trial experience, the patch may offer a low incidence of triptan sensations that include chest tightness, flushing and feelings of pressure and numbness.

About NuPathe
NuPathe Inc. is a biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two proprietary product candidates based on its LAD™, or Long-Acting Delivery, biodegradable implant technology that allows delivery of therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery. NP202, for the long-term treatment of schizophrenia and bipolar disorder, is being developed to address the long-standing problem of patient noncompliance by providing three months of continuous delivery of risperidone, an atypical antipsychotic. NuPathe is actively seeking partnerships to maximize the commercial potential for our pipeline products in the U.S. and territories throughout the world.

For more information about NuPathe, please visit our website and our blog at You can also follow us on StockTwits (, Twitter (, SlideShare ( and LinkedIn (

Contact Information

  • Contact Information:

    Investor Contacts
    John Woolford
    Westwicke Partners, LLC
    (443) 213-0506

    Keith A. Goldan
    Vice President & Chief Financial Officer
    NuPathe Inc.
    (484) 567-0130

    Media Contact
    Jennifer Guinan
    Sage Strategic Marketing
    (610) 410-8111